WO2006066109A3 - Hydroxysteroid dehydrogenase inhibitors - Google Patents

Hydroxysteroid dehydrogenase inhibitors Download PDF

Info

Publication number
WO2006066109A3
WO2006066109A3 PCT/US2005/045704 US2005045704W WO2006066109A3 WO 2006066109 A3 WO2006066109 A3 WO 2006066109A3 US 2005045704 W US2005045704 W US 2005045704W WO 2006066109 A3 WO2006066109 A3 WO 2006066109A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxysteroid dehydrogenase
dehydrogenase inhibitors
inhibitors
hydroxysteroid
kits
Prior art date
Application number
PCT/US2005/045704
Other languages
French (fr)
Other versions
WO2006066109A2 (en
Inventor
Nancy K Brennan
Edcon Chang
Stephen W Kaldor
Andre A Kiryanov
Andrew J Jennings
Jeffrey A Stafford
Original Assignee
Takeda San Diego Inc
Nancy K Brennan
Edcon Chang
Stephen W Kaldor
Andre A Kiryanov
Andrew J Jennings
Jeffrey A Stafford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda San Diego Inc, Nancy K Brennan, Edcon Chang, Stephen W Kaldor, Andre A Kiryanov, Andrew J Jennings, Jeffrey A Stafford filed Critical Takeda San Diego Inc
Priority to JP2007546949A priority Critical patent/JP2008524244A/en
Priority to EP05854426A priority patent/EP1888544A2/en
Publication of WO2006066109A2 publication Critical patent/WO2006066109A2/en
Publication of WO2006066109A3 publication Critical patent/WO2006066109A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: Formula (I) wherein the variables are as defined herein.
PCT/US2005/045704 2004-12-17 2005-12-16 Hydroxysteroid dehydrogenase inhibitors WO2006066109A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007546949A JP2008524244A (en) 2004-12-17 2005-12-16 Hydroxyl steroid dehydrogenase inhibitor
EP05854426A EP1888544A2 (en) 2004-12-17 2005-12-16 Hydroxysteroid dehydrogenase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63733504P 2004-12-17 2004-12-17
US60/637,335 2004-12-17

Publications (2)

Publication Number Publication Date
WO2006066109A2 WO2006066109A2 (en) 2006-06-22
WO2006066109A3 true WO2006066109A3 (en) 2009-04-23

Family

ID=36588605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045704 WO2006066109A2 (en) 2004-12-17 2005-12-16 Hydroxysteroid dehydrogenase inhibitors

Country Status (3)

Country Link
EP (1) EP1888544A2 (en)
JP (1) JP2008524244A (en)
WO (1) WO2006066109A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1846363B1 (en) 2005-01-05 2012-04-25 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CN102816081A (en) 2005-01-05 2012-12-12 雅培制药有限公司 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
RU2007145434A (en) 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) BICYCLIC DERIVATIVES AS ION CHANNEL MODULATORS
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2009001817A1 (en) 2007-06-27 2008-12-31 Taisho Pharmaceutical Co., Ltd. COMPOUND HAVING 11β-HSD1 INHIBITORY ACTIVITY
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
JP5736098B2 (en) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド Pharmaceutical composition for treating central nervous system disorders
UY31968A (en) 2008-07-09 2010-01-29 Sanofi Aventis NEW HETEROCYCLIC DERIVATIVES, THEIR PROCESSES FOR THEIR PREPARATION, AND THEIR THERAPEUTIC USES
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
BR112012027762B1 (en) 2010-04-28 2018-06-05 Bayer Intellectual Property Gmbh CETOHETEROARYLPIPERIDINE AND - PIPERAZINE DERIVATIVES AS FUNGICIDES
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
SG11201809702SA (en) 2016-05-20 2018-12-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
SG10201912372XA (en) 2016-12-09 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
PE20211389A1 (en) 2018-06-13 2021-07-27 Xenon Pharmaceuticals Inc BENZENOSULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
JP7383012B2 (en) 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
PE20211066A1 (en) 2018-08-31 2021-06-09 Xenon Pharmaceuticals Inc SULFONAMIDE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND THEIR USE AS THERAPEUTIC AGENTS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224996A1 (en) * 2000-05-22 2004-11-11 Tjeerd Barf Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224996A1 (en) * 2000-05-22 2004-11-11 Tjeerd Barf Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Also Published As

Publication number Publication date
WO2006066109A2 (en) 2006-06-22
EP1888544A2 (en) 2008-02-20
JP2008524244A (en) 2008-07-10

Similar Documents

Publication Publication Date Title
WO2006066109A3 (en) Hydroxysteroid dehydrogenase inhibitors
WO2006105127A3 (en) Hydroxysteroid dehydrogenase inhibitors
WO2007028135A3 (en) Imidazopyridine compounds
WO2007061923A3 (en) Glucokinase activators
WO2006044687A3 (en) Kinase inhibitors
WO2008055236A3 (en) Mapk/erk kinase inhibitors
WO2007075847A3 (en) Glucokinase activators
WO2008079814A3 (en) Mapk/erk kinase inhibitors
MY146989A (en) Kinase inhibitors
WO2008012532A3 (en) : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
WO2004062613A3 (en) Hiv integrase inhibitors
WO2008076427A3 (en) Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2008115890A3 (en) Mapk/erk kinase inhibitors
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
NO20080784L (en) Histondeacetylaseinhibitorer
WO2005007085A3 (en) Pyrazolo pyrimidine derivatives and methods of use thereof
WO2007136592A3 (en) 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2008060476A3 (en) Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007133352A3 (en) Macrocyclic kinase inhibitors
WO2009003428A3 (en) Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives
WO2008019395A3 (en) Compounds for improving learning and memory
WO2008140553A3 (en) Mapk/erk kinase inhibitors
WO2005085236A3 (en) Caspase inhibitors and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005854426

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007546949

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005854426

Country of ref document: EP